Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia

European Journal of Clinical Pharmacology

Volumn 52, Issue 2, 1997, Pages 101-106

  Raslova K ^a   Dubovska D ^a   Mongiellova V ^a   Trnovec, T ^a  

^a INST OF PREV AND CLINICAL MEDICINE   (Slovakia)

Author keywords

apo B; fenofibric acid plasma level; hyperlipoproteinemia; Hyperlipoproteinemia; cholesterol; LDL cholesterol; Micronized fenofibrate; type IIA; type IIB

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; DRUG METABOLITE; FENOFIBRATE; FENOFIBRIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE 2; LIPID METABOLISM; MALE; PRIORITY JOURNAL;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTILIPEMIC AGENTS; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, LDL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MIDDLE AGED; PROCETOFEN; PROSPECTIVE STUDIES;

EID: 0030950062     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050257     Document Type: Article

References (27)

1. Grundy SM, Vega GL (1987) Fibric acids: Effects on lipids and lipoprotein metabolism. Am J Med 83 [Suppl 5B]: 9-20
2. Schonfeld G (1994) The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 111: 161-174
3. Knopp RH, Brown WV, Dujovne CA, Farquahar JW, Feldman EB (1987) Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med 83 [Suppl 5B]: 50-59
4. Shepherd J (1994) The fibrates in clinical practice: focus on micronized fenofibrate. Atherosclerosis 110 [Suppl]: S55-S63
5. Staels B, Vu-Dac N, Kosykh VA, Saladin R, Fruchart JC, Dallongeville J, Auwerx J (1995) Fibrates downregulate apolipoprotein CIII expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95: 705-712
6. Blane GF (1989) Review of European clinical experience with fenofibrate. Cardiology 76 [Suppl 1]: 1-13
7. Bard JM, Parra HJ, Camare R, Luc G, Ziegler O, Dachet C (1992) A multicenter comparison of the effects of Simvastatin and fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis on lipoproteins defined by their apolipoprotein composition. Metabolism 41: 498-503
8. Caslake MJ, Packard CJ, Gaw A, Murray E, Griffin BA, Vallance BD, Shepherd J (1993) Fenofibrate and LDL metabolic heterogenity in hypercholesterolemia. Arterioscler Thromb 13: 702-711
9. Munoz A, Guichard JP, Reginault PH (1994) Micronized fenofibrate. Atherosclerosis 110 [Suppl]: S45-48
10. Ariëns EJ (1974) Drug levels in the target tissue and effect. Clin Pharmacol Ther 16: 155-175
11. Ariëns EJ, Beld AJ (1977) Commentary: the receptor concept in evolution. Biochem Pharmacol 26: 913-918
12. Goldstein JL, Hobbs HH, Brown MB (1995) Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds), Metabolic and molecular basis of inherited disease, vol 2. McGraw-Hill, New York, pp 1981-2030
13. Kane JP, Havel RJ (1995) Disorders of the biogenesis and secretion of lipoproteins containing the B apolipoproteins. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds), Metabolic and molecular basis of inherited disease, vol 2. McGraw-Hill, New York, pp 1853-1885
14. Watts GF (1990) The hyperlipidemias: classifications, pathogenesis, and clinical findings. In: Cholesterol and coronary heart disease. Discovering the link. Current Medical Literature. London, pp 67-87
15. 2+ precipitation procedure for quantitation of HDL-cholesterol. Clin Chem 28: 1574-1579
16. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of concentration of LDL-cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502
17. Brown WV (1987) Fenofibrate, a third-generation fibric acid derivative. Am J Med 83 [Suppl 5B]: 1-2
18. Hahman MW, Bunte T, Hellwig N, Hau U, Becker D, Dyckmans J, Keller HE, Schieffer HJ (1991) Progression and regression of minor coronary arterial narrowings by quantitative angiography after fenofibrate therapy. Am J Cardiol 67: 957 961
19. Bunte T, Hahmann HW, Hellwig N, Hau U, Becker D, Dyckmans J, Keller HE, Schieffer HJ (1993) Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients. Atherosclerosis 98: 127-138
20. Wagner JG (1968) Kinetics of pharmacologic response. I. Proposed relationship between response and drug concentration in the intact animal. J Theor Biol 20: 173-201
21. Lesko LJ, Williams RL (1994) Regulatory perspective: the role of pharmacokinetics and pharmacodynamics. In: Cutler NR, Sramek JJ, Narang PK (eds) Pharmacodynamics and drug development. Wiley, Chichester, pp 115-130
22. Staels B, Van Tol A, Andreu T, Auwerx J (1992) Fibrates influence the expresion of genes involved in lipoprotein metabolism in a tissue-selective manner in the rat. Arterioscler Thromb 12: 286-294
23. Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guillouzo A, Fruchart JC, Rubin E, Denefle P, Staels B, Brannelec D (1996) Opposite regulation of human cersus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 97: 2408-2416
24. Vu-Dac N, Schoonjans K, Kosikh V, Dallongeville J, Fruchart JC, Staels B (1995) Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 96: 741-750
25. Sirtori CR, Montanari G, Gianfranceschi G, Sirtori M, Galli G, Bosisio E (1985) Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidemic patients. Eur J Clin Pharmacol 28: 619-624
26. Drouin P, Mejean L, Lambert D, Sauvenet JP, Debry G (1979) Drug plasma levels and hypocholesterlolemic effect of fenofibrate in patients with type IIA hyperlipoproteinemia. Curr Ther Res 26: 357-362
27. Weil A, Caldwell J, Strolin-Benedetti M (1990) Metabolism and disposition of 14 C-fenofibrate in human volunteers. Drug Metab Dispos 18: 115-120